Cocrystal Pharma (COCP) Change in Accured Expenses (2010 - 2026)
Cocrystal Pharma (COCP) posted Change in Accured Expenses of $10000.0 for Q1 2026, down 98.53% sequentially from $682000.0 in Q4 2025, and up 101.98% YoY from $4951.0 in Q1 2025.
Cocrystal Pharma (COCP) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Cocrystal Pharma has reported Change in Accured Expenses for 16 years, with the latest figure at $10000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 101.98% year-over-year to $10000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $264000.0 (up 151.06% YoY) and the FY2025 annual result came in at -$251000.0, up 71.96% from the prior year.
- Change in Accured Expenses fell to $10000.0 in Q1 2026 per COCP's latest filing, from $682000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $2.0 million in Q1 2023 and troughed at -$1.5 million in Q2 2023.
- A 5-year average of $34647.1 and a median of $10000.0 in 2026 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 11435.29% in 2023, down 341.98% in 2023.
- Over 5 years, Change in Accured Expenses stood at -$402000.0 in 2022, then surged by 402.49% to $1.2 million in 2023, then tumbled by 61.18% to $472000.0 in 2024, then jumped by 44.49% to $682000.0 in 2025, then sank by 98.53% to $10000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $10000.0, $682000.0, and -$320000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cocrystal Pharma | 15.65 Mn | 13.33 Mn | - | 378,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 378,000.00 |
| Jun 30, 2026 | 378,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 682,000.00 |
| Dec 31, 2025 | 682,000.00 |
| Sep 30, 2025 | -320,000.00 |
| Sep 30, 2025 | -320,000.00 |
| Jun 30, 2025 | -108,000.00 |
| Jun 30, 2025 | -108,000.00 |
| Mar 31, 2025 | -505,000.00 |
| Mar 31, 2025 | -505,000.00 |
| Dec 31, 2024 | 472,000.00 |
| Dec 31, 2024 | 472,000.00 |
| Sep 30, 2024 | -748,000.00 |
| Sep 30, 2024 | -748,000.00 |
| Jun 30, 2024 | 264,000.00 |
| Jun 30, 2024 | 264,000.00 |
| Mar 31, 2024 | -883,000.00 |
| Mar 31, 2024 | -883,000.00 |